Dauntless provides a better way to develop drugs.
The traditional biotech company holds numerous assets at various stages of development, and its investors, management, labs, and staff collectively share interest in all company assets. In contrast, Dauntless uses a one-asset, one-company model. Each asset is held in a separate holding company, with Dauntless managing the development of each asset and employing expert consultants who specialize in the unique requirements of a given asset. This innovative approach facilitates operational efficiency, drug development speed, and a simplified business development structure. The result: lower costs, shorter timelines, higher returns.